DSS, Inc.’s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger

"This transaction reflects our continued commitment to unlocking shareholder value through the strategic development and monetization of our subsidiaries," said Jason Grady, CEO of DSS, Inc. "We believe the combination of Impact's disruptive pipeline with Dr. Ashleys' global infrastructure and commercial expertise will establish a robust, scalable biopharmaceutical platform. It further validates our strategy of creating long- term value by preparing our key assets for public market growth." NEW YORK, June 2 ...